about
The role of steroid hormones in breast cancer stem cellsThe clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic reviewThe value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre.Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment.Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling.Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.Origins of breast cancer subtypes and therapeutic implications.Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.Resistance to endocrine therapy: are breast cancer stem cells the culprits?Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.Advances in the treatment of luminal breast cancer.HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.Breast cancer: current and future endocrine therapies.Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer.Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors.Are health technology assessments of pharmacogenetic tests feasible? A case study ofCYP2D6testing in the treatment of breast cancer with tamoxifenCorrection: Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort studyMicroenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signallingBreast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort studyTargeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer
P50
Q26783658-165296E3-A400-4204-84BA-42AC1EA0272BQ26864285-BA77E687-83B4-468C-8C9C-D65840D31712Q34983316-7FDB59DA-3881-46C4-8E0D-C356DEDE56A3Q36123897-A47E5C04-C8C6-498D-B00E-34793E555602Q36493347-FB6E278E-7AF0-4D36-B420-C9FE0FD73293Q36903382-D4409D12-4451-4DF5-AEBD-85E9E7D98EA3Q36904280-C87F8DDD-5AE1-42AA-BD4F-D0AB81E9CF95Q36922916-993BC0DD-BDF3-4157-AC94-D064BCAB1337Q37022428-D3FF9FBD-9C3B-47CC-9ACB-F041959B180CQ37270066-76A6F215-ECA0-47A4-985F-2BDCB3EF47FDQ37404590-F8FAB081-4BA7-4151-B99E-44F6F658A47EQ37533025-D59A89E6-80CE-4BBB-9DB8-D31943C4B822Q37690257-96AE3F68-B7B2-411D-9D27-0B5918D2F65BQ38072562-170A960F-6F38-4C7A-97DA-EF474AA84302Q38083982-A1C956DD-CD58-467C-9D91-94EB080CB31EQ38128096-0C6473CB-15C0-4404-A6E9-7F0172B5ED37Q38418038-4FA03AE6-664B-4CD0-A2F9-AE21A3DF2F5BQ39752820-852982CB-FD3B-4E01-A0A5-02955B3086AEQ42674340-95ABAD4B-8599-433C-A7B6-C6C7ABBEE852Q43247651-8EB4BFAA-5FE0-498A-84BE-FDFD3F89542FQ52720179-AA24CE1C-61EA-42E8-B453-05381CC19EC8Q57697028-3E026318-63B6-441B-9F38-9CBD6F7BA39DQ90575875-4B41CAB9-9A2B-4D9C-B8B7-7E1CCD39D2BBQ91062672-03DD493E-AAD0-4AF9-87C2-25AA14BBF05AQ93179707-837B32B5-8EEA-4002-AC2D-6DC39F046C92Q96022932-36565441-C8C5-46D4-901C-15AD4A3C6651
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sacha Howell
@ast
Sacha Howell
@en
Sacha Howell
@es
Sacha Howell
@nl
Sacha Howell
@sl
type
label
Sacha Howell
@ast
Sacha Howell
@en
Sacha Howell
@es
Sacha Howell
@nl
Sacha Howell
@sl
prefLabel
Sacha Howell
@ast
Sacha Howell
@en
Sacha Howell
@es
Sacha Howell
@nl
Sacha Howell
@sl
P1053
K-8770-2015
P106
P1153
7402274005
P31
P3829
P496
0000-0001-8141-6515